Loading patent…
AssigneesInstitute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Institut Curie, Institut de Genetique et de Biologie Moleculaire et Cellulaire
InventorsAlfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
Estimating the term…
The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.
A method, comprising administering to a patient having melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, or glioblastoma an inhibitor of thymine DNA glycosylase (TDG) in an amount effective to inhibit TDG in cells of the melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, or glioblastoma, thereby treating the melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, or glioblastoma in the patient.
Dependencies are inferred from the claim text.